ARTICLE
ejd.2012.1705
Auteur(s) : Satoshi Nakamizo, Akiko Arakawa arakawa@kuhp.kyoto-u.ac.jp,
Akihiko Kitoh, Satoshi Kore-Eda, Atsushi Utani, Yoshiki Miyachi
Department of Dermatology,
Kyoto School of Medicine,
54 Shogoin-Kawara, Sakyo,
Kyoto 606-8507, Japan
Muir-Torre syndrome (MTS) is a cancer susceptibility syndrome,
defined as the association of sebaceous tumor and internal
malignancy [1]. Tumors in MTS are characterized by the accumulation
of microsatellite instability (MSI) in a repeated sequence of
genomic DNA [2]. Although the TGF-β signal targeted by MSI is known
to promote human colorectal MSI carcinogenesis [3], the mechanism
of sebaceous tumourigenesis in MTS remains unclear.
A 66-year-old man presented with a 5-month history of skin
tumors located on the right temple and lower abdomen. The patient
had a past history of colon cancer, which had been excised 14 years
before. His family history was significant for cancer
susceptibility; colon cancer in his father and brother, lung cancer
in his mother, and brain cancer in his sister. On physical
examination, the two tumors showed similar phenotypes; one,
ulcerative and centroclinal, 8×10 mm, on the temple and one,
10×13 mm, on the abdomen (figures 1A-B). The
patient underwent wide excision of the two tumors with negative
surgical margins. Histological findings of both tumors confirmed
sebaceous carcinoma, showing sebaceous differentiation, frequent
mitotic figures, and nuclear polymorphisms (figures 1C-D). A
clinical diagnosis of MTS was made, based on the double sebaceous
carcinomas associated with a past history of colon cancer.
Molecular diagnosis of MTS was established by unequivocal MSI in
the tumor genome, compared with genomic stability of the peripheral
blood, which suggested accelerated accumulation of mutations
throughout the tumor genome. Then, screening examinations for
visceral malignancy were examined; colonoscopy revealed hyperplasic
polyps and no clinically detectable cancer. Gastroscopy,
computerized tomography (CT) scan on the head and thoraco-abdominal
region, and urinary cytology did not detect tumors. After 6 months,
he was hospitalized to find the cause of increased abdominal girth.
On his face and abdomen, a total of 6 skin tumors had developed
during this short period, all of which proved to be sebaceous
carcinoma by histopathology. At this time, serum TGF-β1 was
extremely high (16.1 ng/mL, normal 1.56∼3.24 ng/mL). The sebaceous
tumors in this case demonstrated diffuse and cytoplasmic expression
of TGFBR2 (figure 1E),
compared to membranous expressions limited to the outer layers of
nevus sebaceus and sebaceous hyperplasia in non-MTS (figure
1F). Abdominal CT revealed massive ascites, and
multiple lymphadenopathies. Colonoscopy revealed superficial colon
cancer, which had not been detected previously. Peritoneal
metastasis was suspected with unknown origin, since he and his
family refused further examinations.
Transforming growth factor-beta (TGF-β) promotes tumor
development when mutational defects occur in the TGF-β pathway [4].
Since TGF-β signal components have multiple loci targeted by MSI,
aberrant TGF-β signaling plays an important role in progression of
colorectal tumor in MTS [5]. Though the precise mechanism remains
unclear in this case, we speculated that high levels of serum
TGF-β1 might have contributed to the synchronized multiple
development of sebaceous carcinomas in the anatomically remote
sites, probably via TGFBR2 or the other components in TGF-β
pathway.
Disclosure
Financial support: none. Conflict of interest: none.
References
1. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms
as markers of Muir-Torre syndrome: a diagnostic algorithm. J
Cutan Pathol 2009; 36(6):613-9.
2. Boland CR, Thibodeau SN, Hamilton SR, et al. A
National Cancer Institute Workshop on Microsatellite Instability
for cancer detection and familial predisposition: development of
international criteria for the determination of microsatellite
instability in colorectal cancer. Cancer Res 1998;
58(22):5248-57.
3. Bian Y, Caldes T, Wijnen J, et al. TGFBR1*6A
may contribute to hereditary colorectal cancer. J Clin Oncol
2005; 23(13):3074-8.
4. Massague J. TGFbeta in Cancer. Cell 2008;
134(2):215-30.
5. Duval A, Hamelin R. Mutations at coding repeat
sequences in mismatch repair-deficient human cancers: toward a new
concept of target genes for instability. Cancer Res 2002;
62(9):2447-54.
|